Affordable Access

deepdyve-link
Publisher Website

Comparison of the effects of radiotherapy doses of 50.4 Gy and 60 Gy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.

Authors
  • Nemoto, Kenji1, 2
  • Kawashiro, Shohei3, 4
  • Toh, Yasushi3, 5
  • Numasaki, Hodaka3, 6
  • Tachimori, Yuji3, 7
  • Uno, Takashi3, 8
  • Jingu, Keiichi3, 9
  • Matsubara, Hisahiro3, 10
  • 1 Japan Esophageal Society, Tokyo, Japan. [email protected] , (Japan)
  • 2 Department of Radiology, Yamagata University Graduate School of Medicine, 2-2-2, Iida-nishi, Yamagata, 990-9585, Japan. [email protected] , (Japan)
  • 3 Japan Esophageal Society, Tokyo, Japan. , (Japan)
  • 4 Department of Radiology, Yamagata University Graduate School of Medicine, 2-2-2, Iida-nishi, Yamagata, 990-9585, Japan. , (Japan)
  • 5 Department of Gastroenterological Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. , (Japan)
  • 6 Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan. , (Japan)
  • 7 Center for Cancer Treatment, Kawasaki Saiwai Hospital, Kawasaki, Japan. , (Japan)
  • 8 Department of Radiology, Chiba University Hospital, Chiba, Japan. , (Japan)
  • 9 Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan. , (Japan)
  • 10 Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba, Japan. , (Japan)
Type
Published Article
Journal
Esophagus : official journal of the Japan Esophageal Society
Publication Date
Apr 01, 2020
Volume
17
Issue
2
Pages
122–126
Identifiers
DOI: 10.1007/s10388-019-00711-x
PMID: 31912332
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

In definitive chemoradiotherapy (CRTx) for esophageal cancer, a radiotherapy (RT) dose of 50.4 Gy in 28 fractions has been the standard in many countries, while 60 Gy in 30 fractions has been frequently used in Japan. To clarify the optimal RT dose in CRTx for esophageal cancer, we compared clinical outcomes with the two doses using data from the Comprehensive Registry of Esophageal Cancer in Japan by the Japan Esophageal Society (JES). Of the patients enrolled in the registry for 2015-2017 surveys (patients treated between 2009 and 2011), 996 patients who received definitive CRTx with 50.4 Gy or 60 Gy for thoracic esophageal cancer were eligible for analysis. The complete response (CR) rates in the 50.4 Gy and 60 Gy groups were 49.1% and 46.4%, respectively (p = 0.5851). The 5-year overall survival (OS) rates in the 50.4 Gy group and 60 Gy group for stages I, II/III and IV were 64.2% and 57.2%, 35.0% and 27.0%, and 18.0% and 15.3%, respectively. Since no significant difference was found between the two groups, the 50.4 Gy group was not inferior to the 60 Gy group with regard to OS. The analysis revealed that the 50.4 Gy group had a non-inferior outcome in comparison with the 60 Gy group for stages I, II/III and IV thoracic esophageal cancer. These results were obtained from a large database for the first time in Japan.

Report this publication

Statistics

Seen <100 times